Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R

Ellen Weisberg, Atsushi Nonami, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, Hae Yeon Cho, Jianming Zhang, Martin Sattler, Constantine Mitsiades, Kwok Kin Wong, Qingsong Liu, Nathanael S. Gray, James D. Griffin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias. Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clinically. Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents. Experimental Design: A chemical screen using RAS-dependent leukemia cells was developed to identify compounds with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R. Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunoprecipitation and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML). Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RASexpressing cells, and suppression of RAS led to decreases in IGF1R. Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1. In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 week of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone. Drug combination effects observed in cell-based assays were generalized to additional mutant RAS-positive neoplasms. Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clinical investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.

Original languageEnglish
Pages (from-to)5483-5495
Number of pages13
JournalClinical Cancer Research
Volume20
Issue number21
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Leukemia
Up-Regulation
Apoptosis
Gene Knockdown Techniques
S 6
cdc Genes
Drug Combinations
Tumor Burden
Oncogenes
Immunoprecipitation
Immunoblotting
Acute Myeloid Leukemia
Oral Administration
Tail
Veins
Neoplasms
Cell Cycle
Research Design
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. / Weisberg, Ellen; Nonami, Atsushi; Chen, Zhao; Nelson, Erik; Chen, Yongfei; Liu, Feiyang; Cho, Hae Yeon; Zhang, Jianming; Sattler, Martin; Mitsiades, Constantine; Wong, Kwok Kin; Liu, Qingsong; Gray, Nathanael S.; Griffin, James D.

In: Clinical Cancer Research, Vol. 20, No. 21, 01.11.2014, p. 5483-5495.

Research output: Contribution to journalArticle

Weisberg, E, Nonami, A, Chen, Z, Nelson, E, Chen, Y, Liu, F, Cho, HY, Zhang, J, Sattler, M, Mitsiades, C, Wong, KK, Liu, Q, Gray, NS & Griffin, JD 2014, 'Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R', Clinical Cancer Research, vol. 20, no. 21, pp. 5483-5495. https://doi.org/10.1158/1078-0432.CCR-14-0902
Weisberg, Ellen ; Nonami, Atsushi ; Chen, Zhao ; Nelson, Erik ; Chen, Yongfei ; Liu, Feiyang ; Cho, Hae Yeon ; Zhang, Jianming ; Sattler, Martin ; Mitsiades, Constantine ; Wong, Kwok Kin ; Liu, Qingsong ; Gray, Nathanael S. ; Griffin, James D. / Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 21. pp. 5483-5495.
@article{39f499fefc804e80986c3bbd8055515e,
title = "Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R",
abstract = "Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias. Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clinically. Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents. Experimental Design: A chemical screen using RAS-dependent leukemia cells was developed to identify compounds with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R. Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunoprecipitation and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML). Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RASexpressing cells, and suppression of RAS led to decreases in IGF1R. Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1. In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 week of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone. Drug combination effects observed in cell-based assays were generalized to additional mutant RAS-positive neoplasms. Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clinical investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.",
author = "Ellen Weisberg and Atsushi Nonami and Zhao Chen and Erik Nelson and Yongfei Chen and Feiyang Liu and Cho, {Hae Yeon} and Jianming Zhang and Martin Sattler and Constantine Mitsiades and Wong, {Kwok Kin} and Qingsong Liu and Gray, {Nathanael S.} and Griffin, {James D.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1158/1078-0432.CCR-14-0902",
language = "English",
volume = "20",
pages = "5483--5495",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R

AU - Weisberg, Ellen

AU - Nonami, Atsushi

AU - Chen, Zhao

AU - Nelson, Erik

AU - Chen, Yongfei

AU - Liu, Feiyang

AU - Cho, Hae Yeon

AU - Zhang, Jianming

AU - Sattler, Martin

AU - Mitsiades, Constantine

AU - Wong, Kwok Kin

AU - Liu, Qingsong

AU - Gray, Nathanael S.

AU - Griffin, James D.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias. Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clinically. Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents. Experimental Design: A chemical screen using RAS-dependent leukemia cells was developed to identify compounds with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R. Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunoprecipitation and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML). Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RASexpressing cells, and suppression of RAS led to decreases in IGF1R. Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1. In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 week of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone. Drug combination effects observed in cell-based assays were generalized to additional mutant RAS-positive neoplasms. Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clinical investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.

AB - Purpose: Activating mutations in the RAS oncogene occur frequently in human leukemias. Direct targeting of RAS has proven to be challenging, although targeting of downstream RAS mediators, such as MEK, is currently being tested clinically. Given the complexity of RAS signaling, it is likely that combinations of targeted agents will be more effective than single agents. Experimental Design: A chemical screen using RAS-dependent leukemia cells was developed to identify compounds with unanticipated activity in the presence of an MEK inhibitor and led to identification of inhibitors of IGF1R. Results were validated using cell-based proliferation, apoptosis, cell-cycle, and gene knockdown assays; immunoprecipitation and immunoblotting; and a noninvasive in vivo bioluminescence model of acute myeloid leukemia (AML). Results: Mechanistically, IGF1R protein expression/activity was substantially increased in mutant RASexpressing cells, and suppression of RAS led to decreases in IGF1R. Synergy between MEK and IGF1R inhibitors correlated with induction of apoptosis, inhibition of cell-cycle progression, and decreased phospho-S6 and phospho-4E-BP1. In vivo, NSG mice tail veins injected with OCI-AML3-luc+ cells showed significantly lower tumor burden following 1 week of daily oral administration of 50 mg/kg NVP-AEW541 (IGF1R inhibitor) combined with 25 mg/kg AZD6244 (MEK inhibitor), as compared with mice treated with either agent alone. Drug combination effects observed in cell-based assays were generalized to additional mutant RAS-positive neoplasms. Conclusions: The finding that downstream inhibitors of RAS signaling and IGF1R inhibitors have synergistic activity warrants further clinical investigation of IGF1R and RAS signaling inhibition as a potential treatment strategy for RAS-driven malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84908673061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908673061&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-14-0902

DO - 10.1158/1078-0432.CCR-14-0902

M3 - Article

C2 - 25186968

AN - SCOPUS:84908673061

VL - 20

SP - 5483

EP - 5495

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 21

ER -